Pancreatic Cancer Research

ResearcherKagoshima UniversityActive in the last 2 years

Akio Ido

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112426083. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: 5 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 St… Co-author DOI 10.1111/ajco.70041↗
  2. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Last author DOI 10.1200/jco.24.00936↗
  3. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreat… Co-author DOI 10.1038/s41598-024-63172-y↗
  4. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservat… Co-author DOI 10.21203/rs.3.rs-3985196/v1↗
  5. Efficacy and safety of a novel anti-reflux metal stent during neoadjuvant chemotherapy for pancreatic cancer: A prospective multicenter exploratory study. Last author DOI 10.1002/jhbp.1239↗
  6. Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. Co-author DOI 10.1159/000527176↗
  7. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observati… Co-author DOI 10.21203/rs.3.rs-3677172/v1↗
  8. Focal Type 2 Autoimmune Pancreatitis Mimicking Pancreatic Cancer: Treatment with Neoadjuvant Chemotherapy and Surgery. Last author DOI 10.2169/internalmedicine.0224-22↗
  9. Next-Generation Sequencing Analysis of Pancreatic Cancer Using Residual Liquid Cytology Specimens from Endoscopic Ultrasound-Guided Fine-Needle Biopsy: A Prosp… Last author DOI 10.3390/diagnostics13061078↗
  10. Sequential evaluation of MUC promoter methylation using next-generation sequencing-based custom-made panels in liquid-based cytology specimens of pancreatic ca… Co-author DOI 10.1002/dc.25022↗
  11. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study). Co-author DOI 10.1097/mpa.0000000000001859↗
  12. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection. Co-author DOI 10.21873/anticanres.15145↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shiho Arima · 10 shared papers, 2021–2026 · strength 1.44
  2. Junichi Nakazawa · 7 shared papers, 2021–2026 · strength 0.93
  3. Kenji Mitsugi · 7 shared papers, 2021–2026 · strength 0.93
  4. Futa Koga · 7 shared papers, 2021–2026 · strength 0.93
  5. Taro Shibuki · 7 shared papers, 2021–2026 · strength 0.93
  6. Mototsugu Shimokawa · 7 shared papers, 2021–2026 · strength 0.93
  7. Taiga Otsuka · 7 shared papers, 2021–2026 · strength 0.93
  8. Tsuyoshi Shirakawa · 7 shared papers, 2021–2026 · strength 0.93
  9. Azusa Komori · 7 shared papers, 2021–2026 · strength 0.93
  10. Hiroki Taguchi · 7 shared papers, 2021–2026 · strength 0.93
  11. Shinichi Hashimoto · 5 shared papers, 2021–2023 · strength 0.76
  12. Keisuke Miwa · 4 shared papers, 2023–2026 · strength 0.60
  13. Kazuo Nishikawa · 4 shared papers, 2023–2026 · strength 0.60
  14. Shuji Arita · 4 shared papers, 2023–2026 · strength 0.60
  15. Yasunori Kawaguchi · 4 shared papers, 2023–2026 · strength 0.60
  16. Makoto Hinokuchi · 3 shared papers, 2023 · strength 0.51
  17. Michiyo Higashi · 3 shared papers, 2022–2023 · strength 0.48
  18. Takao Ohtsuka · 3 shared papers, 2022–2023 · strength 0.48
  19. Yoshinobu Okabe · 3 shared papers, 2023–2024 · strength 0.40
  20. Tomoko Kodama · 3 shared papers, 2023–2024 · strength 0.40
  21. Norio Ureshino · 3 shared papers, 2021–2023 · strength 0.33
  22. Masaru Fukahori · 3 shared papers, 2021–2023 · strength 0.33
  23. Yasushi Ide · 3 shared papers, 2021–2023 · strength 0.33
  24. Akihide Tanimoto · 2 shared papers, 2022–2023 · strength 0.30
  25. Hiromichi Iwaya · 2 shared papers, 2022–2023 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.